scholarly journals EFFECT OF USING THE NIGHTSCOUT SYSTEM ON METABOLIC CONTROL, SAFETY, AND INCIDENCE OF COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS

2020 ◽  
Vol 73 (7) ◽  
pp. 1427-1433
Author(s):  
Oskar Kublin ◽  
Mariusz Stępień
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Metabolic Control ◽  
Continuous Glucose Monitoring ◽  
Interstitial Fluid ◽  
Glycated Hemoglobin ◽  
Glucose Monitoring ◽  
Glycated Haemoglobin ◽  
Control Group

Introduction: The Nightscout system is a free Do It Yourself solution. This system appeared in Poland in 2016. The concept of the project is to provide insight into measurements from the system of continuous glucose monitoring in interstitial fluid by authorized persons. The aim: The study was carried out to assess the functionality of the Nightscout system and its effect on metabolic control, safety and the incidence of complications in patients with type 1 diabetes mellitus. Material and methods:The study comprised 98 patients with type 1 diabetes. The study was conducted online using an anonymous questionnaire targeted at members of the “Nightscout Polska (Poland)” group on the Facebook. Results: Severe hypoglycaemic episodes with loss of consciousness were more frequent before using the Nightscout system and were reported by 3 adults (1-2 episodes). No severe hypoglycaemic episodes were reported when using the Nightscout system. The number of ketoacidosis episodes was reduced from 5 before using the Nightscout system to 2 episodes during the use of the system in children, and from 3 to 0 episodes in adults. Levels of glycated haemoglobin were lower in patients using the Nightscout system, both compared to control groups and values before the use it. In people using the Nightscout system glycated hemoglobin values were lower than their values before using this system. It was also shown that people using the Nightscout system had lower glycated hemoglobin than people from the control group. Conclusions: Using the Nightscout system can positively affect the safety of insulin therapy and the treatment process of type 1 diabetes. The Nightscout system can be an improvement of the system of continuous glucose monitoring in interstitial fluid.

The impact of real-time continuous glucose monitoring on metabolic control in children with type 1 diabetes

2020 ◽  
Author(s):  
Ruxandra Calapod Ioana ◽  
Irina Bojoga ◽  
Duta Simona Gabriela ◽  
Ana-Maria Stancu ◽  
Amalia Arhire ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real Time ◽  
Metabolic Control ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
The Impact

Glycemic Variability and Insulin Needs in Patients with Type 1 Diabetes Mellitus Supplemented with Vitamin D: A Pilot Study Using Continuous Glucose Monitoring System

2018 ◽  
Vol 14 (4) ◽  
pp. 395-403 ◽  
Author(s):  
Karem Mileo Felício ◽  
Ana Carolina Contente Braga de Souza ◽  
Joao Felicio Abrahao Neto ◽  
Franciane Trindade Cunha de Melo ◽  
Carolina Tavares Carvalho ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Type 1 Diabetes ◽  
Pilot Study ◽  
Type 1 Diabetes Mellitus ◽  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Variability

scholarly journals Impact of ELKa, the Electronic Device for Prandial Insulin Dose Calculation, on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus: A Randomized Controlled Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Agnieszka Kowalska ◽  
Katarzyna Piechowiak ◽  
Anna Ramotowska ◽  
Agnieszka Szypowska
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Metabolic Control ◽  
Electronic Device ◽  
Intervention Group ◽  
Insulin Dosage ◽  
Control Group ◽  
Prandial Insulin

Background. The ELKa system is composed of computer software, with a database of nutrients, and a dedicated USB kitchen scale. It was designed to automatize the everyday calculations of food exchanges and prandial insulin doses. Aim. To investigate the influence of the ELKa on metabolic control in children with type 1 diabetes mellitus (T1DM). Methods. A randomized, parallel, open-label clinical trial involved 106 patients aged <18 years with T1DM, HbA1C≤10%, undergoing intensive insulin therapy, allocated to the intervention group, who used the ELKa (n=53), or the control group (n=53), who used conventional calculation methods. Results. After the 26-week follow-up, the intention-to-treat analysis showed no differences to all endpoints. In per protocol analysis, 22/53 (41.5%) patients reporting ELKa usage for >50% of meals achieved lower HbA1C levels (P=0.002), lower basal insulin amounts (P=0.049), and lower intrasubject standard deviation of blood glucose levels (P=0.023) in comparison with the control. Moreover, in the intervention group, significant reduction of HbA1C level, by 0.55% point (P=0.002), was noted. No intergroup differences were found in the hypoglycemic episodes, BMI-SDS, bolus insulin dosage, and total daily insulin dosage. Conclusions. The ELKa system improves metabolic control in children with T1DM under regular usage. The trial is registered at ClinicalTrials.gov, number NCT02194517.

Sign in / Sign up

Export Citation Format

Share Document